Compounding pharmacies, that produced the weight loss drugs at a fraction of their brand name price, are being forced to stop ...

The FDA is cracking down on off brand weight loss products similar to Ozempic. GLP-1 drugs for weight loss like Wegovy or ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and Zepbound — the brand name of tirzepatide, threatening a workaround that allowed ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

The end of copycat weight-loss drugs When the Food and Drug Administration ... loss drugs Ozempic and Wegovy. There are still ways that companies can get around the compounding regulations and ...

The injectable drug Ozempic is shown Saturday ... 503A and 503B, based on the FDA regulations that govern their operations. The latter is impacted by the ruling, according to industry experts.

On February 21, 2025, the FDA updated its drug shortage list and labeled the shortage of all doses of injectable semaglutide (Ozempic/Wegovy ... compliant with FDA regulations and appropriately ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight ... dosages slightly different from the standard, FDA-approved amounts or including additives such as vitamins ...